There is a relative lack of well-founded prospective studies targeting the association between leadership and employee health, but the few available good studies suggest an important role of leadership on employee job satisfaction, job well-being, sickness absences, and disability pensions. The relationship between leadership and job performance remains unclear.

Work health promotion is valuable on employees' well-being and work ability and productive in terms of less sickness absences. Activities involving exercise, lifestyle, and ergonomics are potentially effective. On the other hand, education and psychological means applied alone do not seem effective. Work health promotion should target both physical and psychosocial environments at work.

No abstract

Statin treatment is an effective lipid-lowering therapy in children with familial hypercholesterolemia. No significant safety issues were identified. Statin treatment seems to be safe in the short term, but long-term safety remains unknown. Children treated with statins should be carefully monitored and followed up by their pediatricians and their care transferred to an adult lipidologist once they reach 18 years of age. Large long-term randomized controlled trials are needed to establish the long-term safety issues of statins.

Any type of rehabilitation may have an effect at an early stage of decreased work ability, being ineffective later on if applied as the only mode of rehabilitation. Where chronic disability is already present, multimodal medical rehabilitation needs to be combined with vocational rehabilitation in order to reduce absenteeism and disability pensions. It is essential that the workplace is integrated into rehabilitation.

No abstract

Psychosocial work factors can predict health outcomes with economic impact.

Analysis 1.1. Comparison 1 Statins versus control, Outcome 1 Change in carotid intima-media thickness (mm).. . Analysis 1.2. Comparison 1 Statins versus control, Outcome 2 Change in serum LDL cholesterol level (%).. .. Analysis 1.3. Comparison 1 Statins versus control, Outcome 3 Change in puberty (Tanner stage > = 1 level).. .. . Analysis 1.4. Comparison 1 Statins versus control, Outcome 4 Change in aspartate aminotransferase levels (> 3x ULN). Analysis 1.5. Comparison 1 Statins versus control, Outcome 5 Change in alanine aminotransferase levels (> 3x ULN). Analysis 1.6. Comparison 1 Statins versus control, Outcome 6 Myopathy: Change in creatine kinase levels (> 10x ULN). Analysis 1.7. Comparison 1 Statins versus control, Outcome 7 Change in flow-mediated dilatation of brachial artery (%). Analysis 1.8. Comparison 1 Statins versus control, Outcome 8 Change in serum total cholesterol levels (%).. .. Analysis 1.9. Comparison 1 Statins versus control, Outcome 9 Change in serum HDL cholesterol levels (%).. .. Analysis 1.10. Comparison 1 Statins versus control, Outcome 10 Change in serum triglyceride levels (%).. .. .